Search

Your search keyword '"A Armuzzi"' showing total 3,710 results
Start Over Author "A Armuzzi"
3,710 results on '"A Armuzzi"'

1. High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis

Author

Marina Martello, Vincenza Solli, Gaia Mazzocchetti, Antonio Giovanni Solimando, Davide Bezzi, Barbara Taurisano, Ajsi Kanapari, Andrea Poletti, Enrica Borsi, Silvia Armuzzi, Ilaria Vigliotta, Ignazia Pistis, Vanessa Desantis, Giulia Marzocchi, Ilaria Rizzello, Lucia Pantani, Katia Mancuso, Paola Tacchetti, Nicoletta Testoni, Cristina Nanni, Elena Zamagni, Michele Cavo, and Carolina Terragna

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Multiple myeloma (MM) is a plasma cell (PC) disorder characterized by skeletal involvement at the time of diagnosis. Recently, cell-free DNA (cfDNA) has been proven to recapitulate the heterogeneity of bone marrow (BM) disease. Our aim was to evaluate the prognostic role of cfDNA at diagnosis according to disease distribution, and to investigate the role of the MM microenvironment inflammatory state in supplying the release of cfDNA. A total of 162 newly diagnosed MM patients were screened using 18F-FDG PET/CT and assessed by ultra low-pass whole genome sequencing (ULP-WGS). High cfDNA tumor fraction (ctDNA) levels were correlated with different tumor mass markers, and patients with high ctDNA levels at diagnosis were more likely to present with metabolically active paraskeletal (PS) and extramedullary (EM) lesions. Moreover, we demonstrated that microenvironment cancer-associated fibroblast (CAFs)-mediated inflammation might correlate with high ctDNA levels. Indeed, a high cfDNA TF level at diagnosis predicted a poorer prognosis, independent of R-ISS III and 1q amplification; the inclusion of >12% ctDNA in the current R-ISS risk score enables a better identification of high-risk patients. ctDNA can be a reliable and less invasive marker for disease characterization, and can refine patient risk.

Published
2024
Full Text
View/download PDF

2. Collagen Paste Injection in Crohn's Disease Perianal Fistula: Long-term Outcomes of a Pilot, Prospective Cohort Study

Author

Carlotta La Raja, Annalisa Maroli, Caterina Foppa, Roberto Gabbiadini, Arianna Dal Buono, Alessandro Armuzzi, Michele Carvello, and Antonino Spinelli

Subjects
perianal crohn's disease, surgical treatment, sphincter sparing techniques, collagen paste, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Objectives: Crohn's perianal fistula represents a challenging condition to treat. Sphincters-preserving surgical techniques are increasingly being adopted as repeated surgical procedures may lead to various degrees of incontinence. This prospective study aims to assess the long-term efficacy of collagen paste application in patients with simple and complex Crohn's perianal fistulas. Methods: Patients with Crohn's perianal fistula (simple or complex) and inactive luminal disease were enrolled. The fistula tract was treated by curettage and injection of acellular, porcine dermal collagen paste between 2019 and 2021. The primary endpoint was the clinical healing of the fistula at 12 and 24 months, defined as the absence of suppuration on clinical examination. The trial was preregistered on a public repository (ClinicalTrials.gov; NCT03776825). Results: Fourteen patients were included in the study, ten patients (71%) had complex perianal fistula. All patients underwent previous fistula operations. Nine patients (64%) reached complete clinical remission at 12 months, two patients (14%) had a clinical recurrence six months after surgery, and three patients (21%) at 12 months follow-up. Three relapsed patients presented postoperative abscesses. Twelve patients (86%) were followed up at 24 months, no further clinical recurrences or complications were observed and the complete healing rate was 58%. No continence disturbances were recorded after collagen paste injection. Conclusions: The results suggest that collagen paste injection may represent a safe and effective option for Crohn's perianal fistulas, worth further investigation in larger trials.

Published
2024
Full Text
View/download PDF

3. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Author

Peyrin‐Biroulet, Laurent, Arkkila, Perttu, Armuzzi, Alessandro, Danese, Silvio, Ferrante, Marc, Jordi Guardiola, Jahnsen, Jørgen, Louis, Edouard, Lukáš, Milan, Reinisch, Walter, Roblin, Xavier, Smith, Philip J, Kwon, Taek, Kim, Jeeyoung, Yoon, Sangwook, Kim, Dong-Hyeon, and Atreya, Raja

Published
2024
Full Text
View/download PDF

4. Optimising surgical anastomosis in ileocolic resection for Crohn’s disease with respect to recurrence and functionality: two international parallel randomized controlled trials comparing handsewn (END-to-end or Kono-S) to stapled anastomosis (HAND2END and the End2End STUDIES)

Author

Haanappel, Anouck E. G., Bellato, Vittoria, Buskens, Christianne J., Armuzzi, Alessandro, van der Bilt, Jarmila D. W., de Boer, Nanne K. H., Danese, Silvio, van der Does de Willebois, Eline M. L., Duijvestein, Marjolijn, van der Horst, Daniëlle, Pellino, Gianluca, Richir, Milan C., Selvaggi, Francesco, Spinelli, Antonino, Vignali, Andrea, Rosati, Riccardo, and Bemelman, Willem A.

Published
2024
Full Text
View/download PDF

5. Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features

Author

Terragna, Carolina, Poletti, Andrea, Solli, Vincenza, Martello, Marina, Zamagni, Elena, Pantani, Lucia, Borsi, Enrica, Vigliotta, Ilaria, Mazzocchetti, Gaia, Armuzzi, Silvia, Taurisano, Barbara, Testoni, Nicoletta, Marzocchi, Giulia, Kanapari, Ajsi, Pistis, Ignazia, Tacchetti, Paola, Mancuso, Katia, Rocchi, Serena, Rizzello, Ilaria, and Cavo, Michele

Published
2024
Full Text
View/download PDF

7. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

Author

Abrahamovych, Orest, Abu-farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Al Kharrat, Houssam, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico, Armuzzi, Alessandro, Ashida, Toshifumi, Augustyn, Monika, Aumais, Guy, Azum, Martín, Baert, Filip, Balaz, Jozef, Balderramo, Domingo, Begun, Jakob, Berova, Temenuzhka, Billiauws, Lore, Blanco, Antonio, Bortlik, Martin, Bossa, Fabrizio, Bunkova, Elena, Cabello, Mercedes, Cao, Qian, Caprioli, Flavio, Cerqueira, Rute, Chachu, Karen, Chamouard, Patrick, Chen, Chunxiao, Chen, Yan, Chen, Baili, Chen, Dongfeng, Chen, Hong, Chen, Youxiang, Chen, Chou-chen, Cheon, Jaehee, Chen, Minhu, Chiu, Cheng-tang, Choi, Changhwan, Chow, Elizabeth, Cicala, Michele, Cintra, Aderson, Danilkiewicz, Wit, Datsenko, Olena, De Hertogh, Gert, De María, Julio, Del Valle Torrealba Medina, Leyanira, Deliang, Liu, Desreumaux, Pierre, Dewint, Pieter, Ding, Shigang, Doherty, Glen, Draganova, Raina, Dutré, Joris, Duvall, George, Egan, Laurence, Fahed, Julien, Fechner, Lars, Fedurco, Miroslav, Ferhat Celik, Aykut, Fernandez, Juan, Filip, Rafal, Fishman, Sigal, Flores, Cristina, Fogel, Ronald, Fowler, Sharyle, Francesconi, Carlos, Fujii, Toshimitsu, Fujiya, Mikihiro, Fukata, Masayuki, Fukuhara, Seiichiro, Furumoto, Yohei, G.Kiss, Gyula, Gachowski, Waldemar, Gao, Xiang, Gasbarrini, Antonio, Gawdis-wojnarska, Beata, Gaya, Daniel, Geccherle, Andrea, Gilletta De Saint Joseph, Cyrielle, Gimenez, Edgardo, Gionchetti, Paolo, Goldin, Eran, Golovchenko, Oleksandr, Gonciarz, Maciej, Gonen, Can, Gonzales, Chad, Gonzalez, Raquel, Gonzalez Segura, Gaston Julian, Gridnyev, Oleksiy, Gu, Fang, Gupta, Nitin, Gyokeres, Tibor, Haines, Melissa, Hebuterne, Xavier, Hedin, Charlotte, Hellstrom, Per, Hilmi, Ida Normiha, Hirai, Fumihito, Hisabe, Takashi, Hlavaty, Tibor, Hoentjen, Frank, Holtmann, Gerald, Horiki, Noriyuki, Horny, Ivo, Horvat, Gyula, Horvath, Frantisek, Hoshi, Namiko, Hosomi, Shuhei, Hospodarskyy, Ihor, Hou, Xiaohua, Hrdlicka, Ludek, Hu, Naizhong, Huang, Vivian, Huang, Caibin, Inaba, Tomoki, Ishiguro, Yoh, Ishihara, Shunji, Ishikawa, Takeshi, Iskandar, Heba, Israeli, Eran, Itaba, Soichi, Ivanishyn, Olha, Izbéki, Ferenc, Jain, Animesh, Jairath, Vipul, Jang, Byung Ik, Jiang, Chunmeng, Jones, Michael, Kagaya, Takashi, Kalimullina, Dilara, Karakina, Marina, Karatas, Ali, Kashimura, Hiroshi, Keret, Dan, Khovaeva, Yaroslava, Kierkus, Jaroslaw, Kim, Taeoh, Kim, Youngho, Kim, Hyo Jong, Klaus, Jochen, Kleczkowski, Dariusz, Klopocka, Maria, Kobayashi, Taku, Kobielusz-gembala, Iwona, Kojima, Yuichiro, Koo, Ja Seol, Kopon, Adam, Kopp, James, Koyama, Fumikazu, Koynarski, Vasil, Kravchenko, Tetiana, Kudo, Masatoshi, Kusunoki, Ryusaku, Kwon, Kwangan, Laclav, Martin, Lago, Paula, Laharie, David, Lasa, Juan, Lateef, Syed, Latinovic Radakovic, Tatjana, Lee, Kang Moon, Leszczyszyn, Jaroslaw, Li, Yan, Liu, Mei, Liu, Eashen, Lobaton Ortega, Triana, Lopatin, Denis, Lopes, Susana, Lovric Jovanovic, Mileva, Lubini, Marcio, Lukas, Milan, Maaser, Christian, Machytka, Evzen, Maemoto, Atsuo, Magro, Fernando, Marcet, Jorge, Marini, Eduardo, Marusawa, Hiroyuki, Matous, Jan, Matsumoto, Takayuki, Mendu, Shoba, Miao, Yinglei, Mihaly, Emese, Miheller, Pal, Ministro, Paula, Miyabayashi, Hideharu, Mohl, Wolfgang, Molnar, Martin, Moore, Gregory, Moran Faienzo, Gabriela, Morral, Eugeni Domenech, Motoya, Satoshi, Murali, Narayanachar, Mustaffa, Nazri Mohamad, Naem, Mohamed, Nakai, Katsuhiko, Nakajima, Koichi, Nakamoto, Yasunari, Nakamura, Masanao, Nancey, Stephane, Navaneethan, Udayakumar, Nawawi, Khairul Najmi Muhammad, Ninomiya, Tomoyuki, Novak, Janos, Oki, Motoji, Oliveira Santana, Genoile, Onizawa, Michio, Ono, Yohei, Osada, Taro, Osipenko, Marina, Owczarek, Danuta, Parente, Jose Miguel, Patel, Kamal, Patel, Bhaktasharan, Pedersen, Peder, Petroniene, Rima, Petrov, Asen, Petrova, Elina, Piquet, Marie-astrid, Pokrotnieks, Juris, Poroshina, Elena, Portela, Francisco, Pruthi, Jatinder S., Prystupa, Lyudmila, Pukitis, Aldis, Qiu, Yun, Rafalsky, Vladimir, Rainis, Tova, Ramos Junior, Odery, Rashid, Mohammed, Rayyan, Yasser, Reshetko, Olga, Ribeiro, Tarsila, Rivero, Montserrat, Roblin, Xavier, Romatowski, Jacek, Rowbotham, David, Ruffinengo, Orlando Enrique, Rydzewska-wyszkowska, Grazyna, Sablin, Oleg, Sai, Souken, Saibeni, Simone, Said, Rosaida Hj. Md., Sakuraba, Hirotake, Samaan, Mark, Sandborn, William, Saruta, Masayuki, Sauk, Jenny, Savarino, Edoardo Vincenzo, Schultz, Michael, Schulze, Joerg, Sedghi, Shahriar, Seidler, Ursula, Seksik, Philippe, Senturk, Omer, Shelton, Edward, Shimizu, Masahito, Shin, Sungjae, Shukla, Richa, Sigal, Michael, Silva Junior, Roberto, Simoes Neto, Joaquim, Siroky Jr., Milan, Smajstrla, Vit, Smid, Vaclav, Smiley, Sarah, Soledad Brunatto, Luciana, Stanislavchuk, Mykola, Stokesberry, David, Stone, Christian, Suiter, Daniel, Suzuki, Takayoshi, Svorcan, Petar, Takagi, Sho, Takagi, Tomohisa, Takamura, Masaaki, Takayama, Tetsuji, Takeuchi, Ken, Tanaka, Akihito, Tanaka, Hiroki, Tanash, Omar, Tang, Wen, Tankova, Ludmila, Teixeira Campos, Luciana, Thin, Lena, Tkachev, Alexander, Tolmanis, Ivars, Tsarynna, Nataliia, Tsonev, Nikolay, Tulassay, Zsolt, Ueo, Tetsuya, Unal, Nalan, Valuyskikh, Ekaterina, Van Dop, Willemijn, Vasilevskaya, Olga, Venugopal, Kannan, Verstockt, Bram, Viamonte, Manuel, Vyshyvanyuk, Vira, Wang, Bangmao, Wang, Xiaoyan, Wang, Jiangbin, Wang, Yufang, Wei, Shu-chen, Weisshof, Roni, Wisam, Sbeit, Wojcik, Katarzyna, Yakovlev, Alexey, Yasuda, Hiroshi, Ye, Byongduk, Yen, Hsu-heng, Yilmaz, Hasan, Yokoyama, Yoko, Yoon, Hyuk, Yoshida, Takeshi, Yurkiv, Andriy, Zaha, Osamu, Zaltman, Cyrla, Zhan, Qiang, Zhang, Hongjie, Zhang, Shutian, Zhu, Lanxiang, Zou, Duowu, Zou, Xiaoping, Zureikat, Firas, Rubin, David T, Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, and Dignass, Axel

Published
2025
Full Text
View/download PDF

8. Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Author

D'Haens, Geert, Taxonera, Carlos, Lopez-Sanroman, Antonio, Nos, Pilar, Danese, Silvio, Armuzzi, Alessandro, Roblin, Xavier, Peyrin-Biroulet, Laurent, West, Rachel, Mares, Wout G N, Duijvestein, Marjolijn, Gecse, Krisztina B, Feagan, Brian G, Zou, Guangyong, Hulshoff, Melanie S, Mookhoek, Aart, Oldenburg, Lotte, Clasquin, Esmé, Bouhnik, Yoram, and Laharie, David

Published
2025
Full Text
View/download PDF

9. Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies

Author

Cristina Bezzio, Carolina Aliai Micol Cavalli, Gianluca Franchellucci, Arianna Dal Buono, Roberto Gabbiadini, Davide Scalvini, Sofia Manara, Alessandra Narcisi, Alessandro Armuzzi, and Simone Saibeni

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Inflammatory bowel diseases (IBD) and psoriasis are chronic inflammatory conditions belonging to the heterogeneous group of immune-mediated inflammatory diseases (IMIDs). A significant bidirectional link between these two entities has been observed, conditioning an increased risk of IBD in patients with psoriasis and vice-versa. Biological therapies used for IBD may lead to the occurrence of psoriasis as a “paradoxical reaction.” The objective of this study is to analyze the current evidence on the association between psoriasis and IBD, particularly finding case reports of the appearance or aggravation of psoriasis under therapy with interleukin-12/23 (IL-12/23) and IL-23 inhibitors. We conducted comprehensive research to identify studies examining the association between psoriasis and IBD and to find case presentations that reported the appearance or aggravation of psoriasis under biologic therapy with IL-12/23 and IL-23 inhibitors up to March 2024. Clinical trials for IL-12/23 and IL-23 inhibitors in IBD were analyzed to find cases of paradoxical psoriasis as registered adverse events. The sources of evidence are PubMed and ClinicalTrials.gov. For each included case report, data on patient characteristics concerning their age, sex, and comorbidities were selected. Moreover, information regarding the indication for biologic therapy, time to onset of paradoxical psoriasis after starting treatment, clinical presentation, and management of the paradoxical psoriasis was extracted. We found 10 reported cases of ustekinumab-induced new-onset or worsening psoriasis and one reported case of paradoxical psoriasis induced by risankizumab in the literature. Four cases of paradoxical psoriasis have been also registered in clinical trials involving ustekinumab treatment in IBD. Psoriasis can constitute a rare paradoxical adverse event of ustekinumab treatment, but further studies are needed to better clarify the cytokine imbalance that leads to this phenomenon induced by inhibition of IL-12/23 and IL-23. Still, few real-world data exist to draw any conclusions, but risankizumab may positively treat psoriasis induced by ustekinumab.

Published
2024
Full Text
View/download PDF

10. The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease

Author

E. Lubrano, A. Armuzzi, S. Scriffignano, C. Felice, F.M. Perrotta, V. Venerito, S. Del Vescovo, R. Ramonda, G. Cassone, F. Atzeni, R. Caporali, F. Conti, E. Gremese, F. Iannone, M. Sebastiani, and E.G. Favalli

Subjects
Peripheral spondyloarthritis, inflammatory bowel disease, holistic management, Medicine, Internal medicine, RC31-1245
Abstract

Objective. To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with inflammatory bowel disease (IBD). Methods. An exhaustive literature search was conducted in PubMed, Embase, Cochrane Database of Systematic Reviews, and Google Scholar to identify relevant studies on pSpA in IBD patients. Titles, abstracts, and full-text articles were screened for relevance. Data on study design, patient characteristics, diagnostic criteria, main findings, and conclusions were extracted from selected articles. Study quality was assessed using appropriate checklists. Information was synthesized narratively to summarize current understanding. Results. pSpA is the most common extraintestinal manifestation in IBD, with a median prevalence of 16%. It worsens quality of life and requires collaboration between gastroenterologists and rheumatologists for optimal diagnosis and treatment. Several “red flags” guide appropriate specialist referral of IBD patients with suspected pSpA. Once the diagnosis is confirmed, the choice of therapy depends on IBD phenotype and patterns of articular/axial involvement. Anti-tumor necrosis factor (TNF) drugs are first-line biologics, with interleukin (IL)-12/23 and IL-23 inhibitors as alternatives for anti-TNF failure. Small molecules like apremilast and Janus kinase inhibitors also have utility. Recommended treatment algorithms exist, but more randomized controlled trials are needed. Conclusions. Early identification of pSpA is crucial in IBD patients to enable timely intervention, prevent structural damage, and minimize disability. A multidisciplinary, holistic approach addressing musculoskeletal and extra-musculoskeletal manifestations is key to optimal patient outcomes.

Published
2024
Full Text
View/download PDF

11. JAK inhibitors: an evidence-based choice of the most appropriate molecule

Author

Luca Antonioli, Alessandro Armuzzi, Massimo C. Fantini, and Matteo Fornai

Subjects
JAK inhibitors, pharmacokinetic, pharmacodynamic, efficacy, safety, Therapeutics. Pharmacology, RM1-950
Abstract

Janus kinase inhibitors (JAKis) represent a fundamental therapeutic tool for the treatment of patients with immune-mediated inflammatory diseases. Although JAKis are often considered a homogeneous class of drugs whose members are thought to be largely interchangeable, there are significant differences in their efficacy and safety profiles. This narrative review analyzes the pharmacokinetic and pharmacodynamic differences among JAKIs, highlighting their clinical relevance based on the most recent available evidence. The article aims to provide rheumatologists, gastroenterologists and dermatologists with practical guidance for choosing the most appropriate JAKi for each patient, given the lack of evidence-based recommendations on this topic, to improve clinical outcomes. Due to its preferential action on JAK1, intestinal metabolization and proven absence of impact on male fertility, filgotinib may be characterized by an improved benefit/risk ratio compared with other less selective JAKis.

Published
2024
Full Text
View/download PDF

12. Drug Development in Inflammatory Bowel Diseases: What Is Next?

Author

Lorenzo Petronio, Arianna Dal Buono, Roberto Gabbiadini, Giulia Migliorisi, Giuseppe Privitera, Matteo Ferraris, Laura Loy, Cristina Bezzio, and Alessandro Armuzzi

Subjects
Crohn’s disease, ulcerative colitis, anti-TL1A antibodies, obefazimod, S1P modulators, anti IL-23, Medicine, Pharmacy and materia medica, RS1-441
Abstract

Background/Objectives: Inflammatory bowel diseases (IBDs), which include Crohn’s disease (CD) and ulcerative colitis (UC), are chronic conditions requiring long-term therapy to maintain remission and improve quality of life. Despite the approval of numerous drugs, IBD continues to present treatment challenges. This review aims to summarize novel therapeutic target agents in phases II and III of development, including sphingosine-1-phosphate receptor modulators (S1P), anti-interleukin-23 (IL-23), and other small molecules and monoclonal antibodies currently under investigation (e.g., anti-TL1A, obefazimod, NX-13, RIPK-inhibitors). Methods: A comprehensive literature search was conducted up to December 2024 to identify relevant articles published in English over the past three–five years, focusing on phase II/III studies for UC and CD. The search included databases such as PubMed, Google Scholar, and the ClinicalTrials.gov portal. Results: Clinical trials underline the potential of novel immunomodulators, including anti-TL1A, obefazimod, NX-13, RIPK inhibitors, and anti-IL-23p19 agents, as promising therapeutic options for IBD. Anti-IL23p19 therapies, such as risankizumab and mirikizumab, alongside guselkumab, exemplify this class’s growing clinical relevance. While some are already in clinical use, others are nearing approval. Conclusions: Ongoing research into long-term safety and the development of personalized treatment strategies remains pivotal to enhance outcomes. Patient stratification and the strategic positioning of these therapies within the expanding treatment landscape are critical for optimizing their clinical impact.

Published
2025
Full Text
View/download PDF

14. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

Author

Borsi, Enrica, Mazzocchetti, Gaia, Dico, Angela Flores, Vigliotta, Ilaria, Martello, Marina, Poletti, Andrea, Solli, Vincenza, Armuzzi, Silvia, Taurisano, Barbara, Kanapari, Ajsi, Pistis, Ignazia, Zamagni, Elena, Tacchetti, Paola, Pantani, Lucia, Mancuso, Katia, Rocchi, Serena, Rizzello, Ilaria, Cavo, Michele, and Terragna, Carolina

Published
2023
Full Text
View/download PDF

15. A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

Author

Mengoli, C., Aronico, N., Lepore, F., Broglio, G., Merli, S., Natalello, G., Alimenti, E., Scalvini, D., Muscarella, S., Agustoni, F., Pagani, A., Chiellino, S., Corallo, S., Musella, V., Cannizzaro, R., Vecchi, M., Caprioli, F., Gabbiadini, R., Dal Buono, A., Premoli, A., Locati, L.D., Buda, A., Contaldo, A., Schiepatti, A., Biagi, F., Morano, D., Cucè, M., Kotsakis, A., De Lisi, G., Lenti, M.V., Ribaldone, D.G., Borrelli de Andreis, F., Vernero, M., Barberio, B., De Ruvo, M., Savarino, E.V., Kav, T., Blesl, A., Franzoi, M., Gröchenig, H.P., Pugliese, D., Ianiro, G., Porcari, S., Cammarota, G., Gasbarrini, A., Spagnuolo, R., Ellul, P., Foteinogiannopoulou, K., Koutroubakis, I., Argyriou, K., Cappello, M., Jauregui-Amezaga, A., Demarzo, M.G., Silvestris, N., Armuzzi, A., Sottotetti, F., Bertani, L., Festa, S., Eder, P., Pedrazzoli, P., Lasagna, A., Vanoli, A., Gambini, G., Santacroce, G., Rossi, C.M., Delliponti, M., Klersy, C., Corazza, G.R., and Di Sabatino, A.

Published
2024
Full Text
View/download PDF

17. Transition care in patients with IBD: The pediatric and the adult gastroenterologist's perspective. Results from a national survey

Author

Castiglione, Fabiana, Scarallo, Luca, Nardone, Olga Maria, Aloi, Marina, Alvisi, Patrizia, Armuzzi, Alessandro, Arrigo, Serena, Bodini, Giorgia, Calabrese, Emma, Ceccarelli, Linda, Fries, Walter, Marseglia, Antonio, Martinelli, Massimo, Milla, Monica, Orlando, Ambrogio, Rispo, Antonio, Rizzello, Fernando, Romano, Claudio, Caprioli, Flavio, and Lionetti, Paolo

Published
2024
Full Text
View/download PDF

18. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

Author

Macaluso, Fabio Salvatore, Caprioli, Flavio, Benedan, Laura, Bezzio, Cristina, Caporali, Roberto, Cauli, Alberto, Chimenti, Maria Sole, Ciccia, Francesco, D'Angelo, Salvatore, Fantini, Massimo Claudio, Festa, Stefano, Iannone, Florenzo, Lubrano, Ennio, Mariani, Paolo, Papi, Claudio, Provenzano, Giuseppe, Pugliese, Daniela, Rispo, Antonio, Saibeni, Simone, Salvarani, Carlo, Variola, Angela, Zenga, Mariangela, Armuzzi, Alessandro, Orlando, Ambrogio, and Gerli, Roberto

Published
2024
Full Text
View/download PDF

23. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., Bezzio, C., Bossa, F., Privitera, A.C., Marchi, S., Roselli, J., Mazzuoli, S., Geccherle, A., Soriano, A., Principi, M.B., Viola, A., Sarpi, L., Cappello, M., D'Incà, R., Mastronardi, M., Bodini, G., Guerra, M., Benedetti, A., Romano, M., Cicala, M., Di Sabatino, A., Scaldaferri, F., De Rosa, T., Giardino, A.M., Germano, V., Orlando, A., and Armuzzi, A.

Published
2024
Full Text
View/download PDF

25. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves

Author

Cristina Bezzio, Marta Vernero, Stefania Costa, Alessandro Armuzzi, Gionata Fiorino, Sandro Ardizzone, Jenny Roselli, Sonia Carparelli, Ambrogio Orlando, Flavio Andrea Caprioli, Fabiana Castiglione, Chiara Viganò, Davide G. Ribaldone, Fabiana Zingone, Rita Monterubbianesi, Nicola Imperatore, Stefano Festa, Marco Daperno, Ludovica Scucchi, Antonio Ferronato, Luca Pastorelli, Eleonora Alimenti, Paola Balestrieri, Chiara Ricci, Maria Cappello, Carla Felice, Francesca Coppini, Patrizia Alvisi, Imma Di Luna, Viviana Gerardi, Angela Variola, Silvia Mazzuoli, Marco Vincenzo Lenti, Simone Saibeni, and the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)’s COVID-19 Study Group

Subjects
SARS-CoV-2, COVID-19, Outcome, Pandemic, Inflammatory bowel disease, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background In Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves. Methods Observational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020. Results We enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean ± SD: 46.3 ± 16.2 vs. 44.1 ± 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p

Published
2023
Full Text
View/download PDF

26. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management

Author

Sands, Bruce E, Colombel, Jean-Frédéric, Ha, Christina, Farnier, Michel, Armuzzi, Alessandro, Quirk, Daniel, Friedman, Gary S, Kwok, Kenneth, Salese, Leonardo, Su, Chinyu, and Taub, Pam R

Subjects
Arthritis, Nutrition, Inflammatory Bowel Disease, Autoimmune Disease, Clinical Research, Atherosclerosis, Cardiovascular, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Inflammatory and immune system, Good Health and Well Being, Arthritis, Rheumatoid, Cardiovascular Diseases, Cholesterol, Clinical Trials, Phase III as Topic, Colitis, Ulcerative, Heart Disease Risk Factors, Humans, Inflammation, Lipids, Lipoproteins, HDL, Lipoproteins, LDL, Piperidines, Protein Kinase Inhibitors, Psoriasis, Pyrimidines, Pyrroles, Risk Factors, Treatment Outcome, clinical trials, lipids, tofacitinib, clinical trials, Clinical Sciences, Gastroenterology & Hepatology
Abstract

BackgroundPatients with ulcerative colitis (UC) are at elevated risk of cardiovascular disease vs the general population, despite a lower prevalence of traditional risk factors, including hyperlipidemia. Mechanistic studies in patients with rheumatoid arthritis and psoriasis suggest that tofacitinib restores serum lipids to preinflammation levels by reversing inflammation-induced cholesterol metabolism changes. We reviewed data on lipid levels and cardiovascular events, alongside recommendations for managing lipid levels during tofacitinib treatment in patients with UC, based on up-to-date expert guidelines.MethodsData were identified from a phase 3/open-label, long-term extension (OLE) tofacitinib UC clinical program (cutoff May 27, 2019). Literature was identified from PubMed (search terms "lipid," "cholesterol," "lipoprotein," "cardiovascular," "inflammation," "atherosclerosis," "tofacitinib," "rheumatoid arthritis," "psoriasis," "inflammatory bowel disease," "ulcerative colitis," "hyperlipidemia," and "guidelines") and author knowledge. Data were available from 4 phase 3 clinical trials of 1124 patients with moderately to severely active UC who received ≥1 dose of tofacitinib 5 or 10 mg twice daily in induction (two identical trials), maintenance, and OLE studies (treatment duration ≤6.8 years; 2576.4 patient-years of drug exposure).ResultsIn the OLE study, tofacitinib treatment was not associated with major changes from baseline in total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, total cholesterol/high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol, with lipid levels and ratios generally remaining stable over time. The major adverse cardiovascular events incidence rate was 0.26/100 patient-years (95% confidence interval, 0.11-0.54).ConclusionsLipid levels and ratios remained generally unchanged from baseline in the OLE study after tofacitinib treatment, and major adverse cardiovascular events were infrequent. Long-term studies are ongoing.Clinicaltrials.gov identifiersNCT01465763, NCT01458951, NCT01458574, NCT01470612.

Published
2021

33. Radiomics could predict surgery at 10 years in Crohn's disease

Author

Laterza, Lucrezia, Boldrini, Luca, Tran, Huong Elena, Votta, Claudio, Larosa, Luigi, Minordi, Laura Maria, Maresca, Rossella, Pugliese, Daniela, Zocco, Maria Assunta, Ainora, Maria Elena, Lopetuso, Loris Riccardo, Papa, Alfredo, Armuzzi, Alessandro, Gasbarrini, Antonio, and Scaldaferri, Franco

Published
2023
Full Text
View/download PDF

34. Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn′s Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal TransitionSummary

Author

Giulia Rizzo, Federica Rubbino, Sudharshan Elangovan, Giusy Sammarco, Sara Lovisa, Silvia Restelli, Samuel Elias Pineda Chavez, Luca Massimino, Luigi Lamparelli, Marianna Paulis, Annalisa Maroli, Giulia Roda, Mohammad Shalaby, Michele Carvello, Caterina Foppa, Sheona P. Drummond, Paola Spaggiari, Federica Ungaro, Antonino Spinelli, Alberto Malesci, Alessandro Repici, Anthony J. Day, Alessandro Armuzzi, Silvio Danese, and Stefania Vetrano

Subjects
Perianal Fistula, Crohn′s Disease, TSG-6, Extracellular Matrix, EMT, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background and Aims: Perianal fistula represents one of the most disabling manifestations of Crohn′s disease (CD) due to complete destruction of the affected mucosa, which is replaced by granulation tissue and associated with changes in tissue organization. To date, the molecular mechanisms underlying perianal fistula formation are not well defined. Here, we dissected the tissue changes in the fistula area and addressed whether a dysregulation of extracellular matrix (ECM) homeostasis can support fistula formation. Methods: Surgical specimens from perianal fistula tissue and the surrounding region of fistulizing CD were analyzed histologically and by RNA sequencing. Genes significantly modulated were validated by real-time polymerase chain reaction, Western blot, and immunofluorescence assays. The effect of the protein product of TNF-stimulated gene-6 (TSG-6) on cell morphology, phenotype, and ECM organization was investigated with endogenous lentivirus-induced overexpression of TSG-6 in Caco-2 cells and with exogenous addition of recombinant human TSG-6 protein to primary fibroblasts from region surrounding fistula. Proliferative and migratory assays were performed. Results: A markedly different organization of ECM was found across fistula and surrounding fistula regions with an increased expression of integrins and matrix metalloproteinases and hyaluronan (HA) staining in the fistula, associated with increased newly synthesized collagen fibers and mechanosensitive proteins. Among dysregulated genes associated with ECM, TNFAI6 (gene encoding for TSG-6) was as significantly upregulated in the fistula compared with area surrounding fistula, where it promoted the pathological formation of complexes between heavy chains from inter-alpha-inhibitor and HA responsible for the formation of a crosslinked ECM. There was a positive correlation between TNFAI6 expression and expression of mechanosensitive genes in fistula tissue. The overexpression of TSG-6 in Caco-2 cells promoted migration, epithelial–mesenchymal transition, transcription factor SNAI1, and HA synthase (HAs) levels, while in fibroblasts, isolated from the area surrounding the fistula, it promoted an activated phenotype. Moreover, the enrichment of an HA scaffold with recombinant human TSG-6 protein promoted collagen release and increase of SNAI1, ITGA4, ITGA42B, and PTK2B genes, the latter being involved in the transduction of responses to mechanical stimuli. Conclusions: By mediating changes in the ECM organization, TSG-6 triggers the epithelial–mesenchymal transition transcription factor SNAI1 through the activation of mechanosensitive proteins. These data point to regulators of ECM as new potential targets for the treatment of CD perianal fistula.

Published
2023
Full Text
View/download PDF

36. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology

Author

Bertani, Lorenzo, Bezzio, Cristina, Bodini, Giorgia, Bossa, Fabrizio, Buda, Andrea, Calabrese, Emma, Furfaro, Federica, Leone, Salvatore, Mocciaro, Filippo, Onali, Sara, Pastorelli, Luca, Previtali, Enrica, Principi, Mariabeatrice, Renna, Sara, Ribaldone, Davide Giuseppe, Rispo, Antonio, Rizzello, Fernando, Saibeni, Simone, Sampietro, Gianluca Matteo, Savarino, Edoardo, Testa, Anna, Variola, Angela, Viscido, Angelo, Ardizzone, Sandro, Biancone, Livia, Cappello, Maria, Castiglione, Fabiana, Ciccocioppo, Rachele, Comberlato, Michele, Costa, Francesco, D'Incà, Renata, Danese, Silvio, Di Sabatino, Antonio, Fries, Walter, Gionchetti, Paolo, Latella, Giovanni, Manguso, Francesco, Mastronardi, Mauro, Meucci, Gianmichele, Milla, Monica, Scribano, Maria Lia, Vecchi, Maurizio, Macaluso, Fabio Salvatore, Papi, Claudio, Orlando, Ambrogio, Festa, Stefano, Pugliese, Daniela, Bonovas, Stefanos, Pansieri, Claudia, Piovani, Daniele, Fiorino, Gionata, Fantini, Massimo Claudio, Caprioli, Flavio, Daperno, Marco, and Armuzzi, Alessandro

Published
2023
Full Text
View/download PDF

39. Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients

Author

Enrica Borsi, Ilaria Vigliotta, Andrea Poletti, Gaia Mazzocchetti, Vincenza Solli, Luca Zazzeroni, Marina Martello, Silvia Armuzzi, Barbara Taurisano, Ajsi Kanapari, Ignazia Pistis, Elena Zamagni, Lucia Pantani, Serena Rocchi, Katia Mancuso, Paola Tacchetti, Ilaria Rizzello, Simonetta Rizzi, Elisa Dan, Barbara Sinigaglia, Michele Cavo, and Carolina Terragna

Subjects
clonal hematopoiesis of indeterminate potential (CHIP), single-cell DNA sequencing, stem cells, multiple myeloma, Cytology, QH573-671
Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) refers to the phenomenon where a hematopoietic stem cell acquires fitness-increasing mutation(s), resulting in its clonal expansion. CHIP is frequently observed in multiple myeloma (MM) patients, and it is associated with a worse outcome. High-throughput amplicon-based single-cell DNA sequencing was performed on circulating CD34+ cells collected from twelve MM patients before autologous stem cell transplantation (ASCT). Moreover, in four MM patients, longitudinal samples either before or post-ASCT were collected. Single-cell sequencing and data analysis were assessed using the MissionBio Tapestri® platform, with a targeted panel of 20 leukemia-associated genes. We detected CHIP pathogenic mutations in 6/12 patients (50%) at the time of transplant. The most frequently mutated genes were TET2, EZH2, KIT, DNMT3A, and ASXL1. In two patients, we observed co-occurring mutations involving an epigenetic modifier (i.e., DNMT3A) and/or a gene involved in splicing machinery (i.e., SF3B1) and/or a tyrosine kinase receptor (i.e., KIT) in the same clone. Longitudinal analysis of paired samples revealed a positive selection of mutant high-fitness clones over time, regardless of their affinity with a major or minor sub-clone. Copy number analysis of the panel of all genes did not show any numerical alterations present in stem cell compartment. Moreover, we observed a tendency of CHIP-positive patients to achieve a suboptimal response to therapy compared to those without. A sub-clone dynamic of high-fitness mutations over time was confirmed.

Published
2024
Full Text
View/download PDF

41. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Author

Gornet, Jean-Marc, Beaugerie, Laurent, Shaji, Sebastian, Peyrin-Biroulet, Laurent, Reimund, Jean-Marie, Hebuterne, Xavier, Amiot, Aurélien, Armelao, Franco, Blanc, Pierre, Papi, Claudio, De Chambrun, Guillaume Pineton, Roblin, Xavier, Chu, Karmiris, Konstantinos, Shariq, Sohail, Viazis, Nikolaos, Limdi, Jimmy, Eder H, Piotr, Michalopoulos, Georgios, Bell, Andrew, Biancone, Livia, Dewitte, Marie, Mazhar, Zia, Franchimont, Denis, Nancey, Stephane, Macaigne, Gilles, Principi, Maria Beatrice, Fumery, Mathurin, Parkes, Gareth, Valats, Jean-Christophe, Doherty, Glen, Bouguen, Guillaume, Molnar, Tamás, Tsai, Hersin, Gangi, Mohsin, Pedersen, Natalia, Heluwaert, Frédéric, Shenderey, Richard, Zeissig, Sebastian, Butterworth, Jeffrey, Castiglione, Fabiana, Corless, Lynsey, Zallot, Camille, Baert, Filip, Singh, Salil, Sonwalkar, Sunil, Clayton, Elizabeth, Rahier, Jean-François, Vani, Deven, Bellaiche, Guy, De Vos, Martine, Kirchgesner, Julien, Kopylov, Uri, Lobaton, Triana, Locher, Christophe, Mantzaris, Gerassimos, Abouda, George, Smith, Katie, Sprakes, Michael, Theodoropoulou, Angeliki, Wesley, Emma, Bonnet, Joëlle, Elphick, David, Gilletta, Cyrielle, Gordon, John, Laharie, David, Nakad, Antoine, Orlando, Ambrogio, Dubois, Patrick, Hasselblatt, Peter, Michiels, Christophe, Preston, Cathryn, Staicu, Anca, Vuitton, Lucine, Kaassis, Mehdi, Speight, Ally, Ghosh, Deb, Löwenberg, Mark, Mathieu, Nicolas, Pelletier, Anne-Laure, Phillips, Anne, Magro, Fernando, Altwegg, Romain, Avni, Irit, biron, Landy, Jonathon, Nachury, Maria, Shenoy, Achuth, Trang, Caroline, Abitbol, Vered, Bamias, Georgios, Farkas, Klaudia, Maaser, Christian, Shitrit, Ariella, Siegmund, Britta, Filippi, Jérôme, O'morain, Colm, Yanai, Henit, Costes, Laurent, Hobday, David, Szepes, Zoltán, Calabrese, Emma, Dallal, Helen, Fung, Michael, Ramadas, Arvind, Baburajan, Bijay, Koss, Konrad, Barberis, Christophe, Buisson, Anthony, Amil, Morgane, Balestrieri, Paola, Johnson, Matthew, Tzouvala, Maria, Viennot, Stéphanie, Nagy, Ferenc, Thompson, Nick, Alric, Laurent, Samuel, Sunil, Bourrier, Anne, Chanteloup, Elise, Del Tedesco, Emilie, Harbord, Marcus, Lobo, Alan, Myers, Sally, Pollok, Richard, Ahmad, Tariq, Chaudhary, Rakesh, Karakoidas, Christos, Soliman, Ashraf, Stefanescu, Carmen, Theocharis, Georgios, Branden, Stijn Vanden, Beltran, Belén, Bouhnik, Yoram, Bourreille, Arnaud, Branco, Joana, Colleypriest, Ben, Eliakim, Rami, Knight, Paul, O'toole, Aoibhlinn, Robles, Virgina, Triantafyllou, Konstantinos, Bosca, Marta Maia, Lambrecht, Guy, Mosquera, Lucia Marquez, Panter, Simon, Pappa, Aikaterini, Simon, Marion, Sivaji, Ganesh, Bellanger, Christophe, Belle, Arthur, Borruel, Natalia, Egan, Laurence, Peeters, Harald, Sharpstone, Daniel, Arasaradnam, Ramesh, Benitez, José Manuel, Dahlerup, Jens Frederik, Giouleme, Olga, Gisbert, Javier P., Helwig, Ulf, Minguez, Miguel, Tsironi, Eftychia, Variola, Angela, Allen, Patrick, Boivineau, Lucille, Cole, Andy, Dib, Nina, Gomollon, Fernando, Johnston, Richard, Katsanos, Konstantinos, Kennedy, Nick, Kiszka-Kanowitz, Marianne, Marin-Jimenez, Ignacio, Miheller, Pál, Nos, Pilar, Saraj, Othman, Vinter-Jensen, Lars, Zittan, Eran, Baudry, Clotilde, Calvet, Xavier, Cazelles-Boudier, Marie-Christine, Coenegrachts, Jean-Louis, Cullen, Garret, Daperno, Marco, Dhar, Anjan, Gerard, Romain, Jensen, Nanna, Maharshak, Nitsan, Mcalindon, Mark, Mcloughlin, Simon, Parkes, Miles, Patel, Kamal, Peixoto, Armando, Polymeros, Dimitrios, Portela, Francisco, Rocca, Rodolfo, Seksik, Philippe, Subramanian, Sreedhar, Tennenbaum, Ruth, Atreya, Raja, Bachmann, Oliver, Berger, Arthur, Bor, Renáta, Buckley, Maire, Carpio, Daniel, Chaparro, María, Costa, Francesco, Domenech, Eugeni, Esteve, Maria, Foley, Stephen, Guardiola, Jordi, Koutroubakis, Ioannis, Kuehbacher, Tanja, Landman, Cécilia, Lavagna, Alessandro, Manceñido, Noemí, Mañosa, Míriam, Martín-Arranz, Maria Dolores, Plastaras, Laurianne, Scribano, Maria Lia, Sengupta, Subhasish, Teich, Nils, Tran-Minh, My-Linh, Zampeli, Evanthia, Amininejad, Leila, Arroyo, Teresa, Attar, Alain, Backman, Ann-Sofie, Bálint, Anita, Beckly, John, Ben Horin, Shomron, Bernardo, Sónia, Caillo, Ludovic, Caron, Bénédicte, Shanika de Silva, María, FábiáN, Anna, Fiorino, Gionata, Gutierrez, Ana, Lahat, Adi, Masmoudi, Mohamed, Mendolaro, Marco, Muls, Vinciane, Poullenot, Florian, Probert, Christopher, Reenaers, Catherine, Rutka, Mariann, Sarwari, Zaman, Sayer, Joanne, Sicilia, Beatriz, Sousa, Helena, van Kemseke, Catherine, Zabana, Yamile, Astegiano, Marco, Banim, Paul, Bettenworth, Dominik, Boualit, Médina, Brodersen, Jacob Broder, Christidou, Angeliki, Cooney, Rachel, Pinto, João Cortez, Cravo, Portugal Marília, Cremer, Anneline, Danese, Silvio, di Sabatino, Antonio, Fallingborg, Jan, Ferronato, Antonio, Planella, Esther Garcia, Gupta, Sanjay, Halfvarson, Jonas, Israeli, Eran, Kestenbaum, Samantha, Larsen, Lone, Macken, Elisabeth, Mathou, Nicoletta, Milassin, Ágnes, Pofelski, Joanna, Ricci, Chiara, Rodriguez-Moranta, Francisco, Schmidt-Lauber, Martin, Shaw, Ian, Soares, Marta, Soliman, Heithem, Triantos, Christos, Zografos, Konstantinos, Agrawal, Anurag, Armuzzi, Alessandro, Aubourg, Alexandre, Acosta, Manuel Barreiro-de, Barrio, Jesús, Bergemalm, Daniel, Bermejo, Fernando, Bodini, Giorgia, Bohr, Johan, Bossuyt, Peter, Christodoulou, Dimitrios, Claessens, Christophe, Collins, Paul, de Francisco, Ruth, Garcia, Santiago, Georgopoulos, Sotirios, Goutorbe, Felix, Kalantzis, Chrisostomos, Kourikou, Anastasia, Mace, Vincent, Malamut, Georgia, Ministro, Paula, Larmurier, Isabelle Nion, Ricart, Elena, Serrero, Mélanie, Sheridan, Juliette, Weimers, Petra, Andersen, Vibeke, Arroja, Bruno, Bokemeyer, Bernd, Bujanda, Luis, Degand, Thibault, Eriksson, Carl, Garceau, Cécile, Glerup, Henning, Goren, Idan, Jackson, Lucina, Koch, Stéphane, Mesonero, Francisco, Ordas, Ingrid, Riviere, Pauline, Saibeni, Simone, Soares, João, Tavernier, Noémie, Theede, Klaus, Ungar, Bella, Bästlein, Elke, Gasbarrini, Antonio, Protopapas, Andreas, Reindl, Wolfgang, Bossa, Fabrizio, Hart, Ailsa, Heil, Franz-Josef, O'Connor, Anthony, Oldenburg, Bas, Pastorelli, Luca, Stephen patchett, Ramakrishnan, Subramaniam, de Caestecker, John, Echarri, Ana, Kevans, David, Büning, Jürgen, Coelho, Rosa, Jansen, Jeroen, Koslowski, Benjamin, Wells, Christopher, Ceballos, Daniel, König, Ingrid, Padmanabhan, Hari, Patani, Timi, Qureshi, Raheel, Zagorowicz, Edyta, Allez, Matthieu, Archavlis, Emmanouil, Bonnet, Delphine, Guidi, Luisa, Mcnamara, Deirdre, Vernia, Piero, Weidenhiller, Michael, Alon, Lang, Boysen, Trine, Delattre, Charlotte, Farrell, Richard, Krüger, Rolf-Achim, Paupard, Thierry, Vind, Ida, Caprioli, Flavio, Gancho, Vladimir, Quentin, Vincent, Avidan, Benjamin, D’Haens, Geert, Mccarthy, Jane, Snook, Jonathon, Soufleris, Konstantinos, Zerbib, Frank, Carter, Dan, Depla, Annekatrien, Eisenbach, Thomas, Fries, Walter, Grammatikos, Nikolaos, Ilegems, Saskia, Lopez-Sanroman, Antonio, Moreau, Jacques, Riegler, Gabriele, Rietdijk, Svend, Rocha, Marta, Rosa, Isabelle, Ryan, Barbara, Yeremenko, Yelena, Boruchowicz, Arnaud, Damião, Filipe, Laoudi, Foteini, Lügering, Andreas, Macarri, Giampiero, Thomopoulos, Konstantinos, Barros, Luísa, Blixt, Thomas, Garros, Aurélien, Khorrami, Sam, Sokol, Harry, Sturm, Andreas, Livovsky, Dan, Maul, Jochen, Miks, Heinrich, Papadopoulos, Vasileios, Schmidt, Carsten, Snir, Yifat, Svenningsen, Lise, Ahmed, Wafaa, Broitman, Yelena, Cuillerier, Emmanuel, Kant, Prashant, Leyden, Jan, Lichtenstein, Lev, Lopes, Susana, Martineau, Chloé, Mulcahy, Hugh, Schweitzer, Axel, Van Schaik, Fiona, Banai, Hagar, Danion, Pauline, Dulery, Charlotte, Fidder, Herma, Gay, Claire, Hagege, Hervé, Harnois, Florence, Jørgensen, Søren Peter, Müller-Ziehm, Jens, Oikonomou, Michail, Palmela, Carolina, Schulze/Röske, Jörg, Smith, Mark, Thurm, Tamar, Bresso, Francesca, Brixi, Hedia, Jones, John, Macmathuna, Padraig, Painchart, Claire, Ron, Yulia, Vester-Andersen, Marianne, Alexandrino, Gonçalo, Börner, Norbert, Cardoso, Mariana, Chagas, Cristina, Dignaß, Axel, Dotan, Iris, Hedin, Charlotte, Karatzas, Pantelis, Kasapidis, Panagiotis, Palatka, Károly, Sakizlis, Georgios, Wilson, Ana, Bosanko, Nick, Caldeira, Paulo, Gagniere, Charlotte, Libier, Louise, Meunier, Camille, Moog, Gero, Pasquion, Audrey, Pica, Roberta, Akbar, Ayesha, Arab, Nadia, Cadiot, Guillaume, Carvalho, João, Charpignon, Claire, Fellermann, Laus, Fishman, Sigal, Fraser, Gerald, Gluck, Nathan, Hoesl, Mark, Kierkus, Jarosław, Klopocka, Maria, Arranz, Eduardo Martin, Menchen, Luis, Nikolaus, Susanna, Petrache, Anca, Ponsioen, Cyriel, Riestra, Sabino, Robledo, Pilar, Rodriguez, Cristina, Samer, Misheal, Tischer, Matthias, Wypych, Joanna, Baudon, Julien, Bezzio, Cristina, Boschetti, Gilles, Burisch, Johan, Creed, Tom, Demarzo, Maria Giulia, Festa, Stefano, Figueroa, Andrés, Julsgaard, Mette, Navarro, Pablo, Perez-Galindo, Pablo, Rouillon, Cléa, Sablich, Emanuele, Tosca, Joan, Vidon, Mathias, Vidon, Marine, Vitte, René-Louis, Wampach, Anne, Baumann, Cédric, Urmes, Isabelle Clerc, Rousseau, Hélène, Borie, Marc, Uzzan, Mathieu, Chatten, Kelly, Peter, Rimmer, Tariq, Iqbal, Cossignani, Marta, Cañete, Fiorella, Holvoet, Tom, Krasz, Susanne, Dias, Sandra, Abalia, Hadas, Abaza, Aziza, Abramovich, Gal, Ackzell, Ingrid, Adams, Carol, Addleton, Catherine, Alfambra, Erika, Algaba, Alicia, Allcock, Clare, Allison, Joanna, Amouriaux, Karine, Anderson, Julie, Anderson, Emma, Appelmans, Saskia, Armstrong, Lisa, Atkins, Stacey, Attaran-Bandarabadi, Masoumeh, Bailey, Yvonne, Bardot, Stephanie, Beck, Natasha, Bennett, Lillie, Bergfeld, Jonathan Phil, Berkane, Ramdane, Boey, Hanne, Bowlas, Louise, Bradley-Potts, Joanne, Brear, Tracy, Bretlander-Peters, Nicole, Brown, Ellen, Brown, Johanna, Buckingham, Elizabeth, Buellens, Katrien, Bull, Rhian, Burke, Maura, Burns, Leighanne, Burton, Julie, Bwalya, Agness, Cabanas, Karine, Callaghan, Muriel, Camou, Océane, Campbell, Debbie, Capoferro, Elvira, Carnahan, Mandy, Carnio, Cornelia, Carter, Anne, Clack, Concetta Casali, Chedouba, Leïla, Cipriano, Bessie, Claeys, Sophie, Closset, Manon, Coban, Dilek, Cococcia, Sara, Coe, Carolann, Cole, Helen, Collet, Emilie, Collins, Kayleigh, Combes, Isabelle, Connor, Emma, Constantin, Kathryn, Cooke, Susan, Cornet, Nathanaëlle, Corrihons, Estelle, Corsino, Pilar, Cortaville, Rosie, Cotterill, Donna, Cowton, Amanda, Cox, Harriet, Cripps, Viktoria, Crowder, Amanda, Cukier, Tzufit, Daniel, Amelia, Dawe, Chris, de Haan, Jose, Croix, Rosanna de la, Dejonckheere, Evva, Villanegro, Juan Delare, Delaval, Guillaume, Delliponti, Mariangela, Delommez, Aude, Detry, Emilie, Dhanaratne, Melanie, Galan, Laura Diez, Dodel, Marie, Dooks, Emma, Du Cheyron, Joseph, Duane, Linda, Vulgo Cochran, Jennifer Dulling, Dyer, Simona, Dymond, Harvey, Ekblad, Charlotte, Elliott, Kerry, Emmerson, Ingrid, Eugene-Jolchine, Irène, Fleming, Lorna, Fletcher, Eve, Ford, Sarah, Forshaw, Greg, Foulds, Angela, Francois, Caroline, Fuge, Nicole, Gafni, Gal, Ganon, Miri, Nuñez, Olga Garcia, Ramirez, Laura Garcia, Gelder, Sophie, Gettkowski, Raimonda, Gilardi, Daniela, Giuffrida, Paolo, Gobert, Vincent, Godden, Jo, Godwin, Nuala, Goulden, Kay, Graham, Sharon, Green, Charlotte, Green, Marie, Gueye, Aboubakar, Guler, Tuba, Gustavsson, Ida, Hadjisavvas, Helena, Hammonds, Fiona, Hantzi, Christina, Hauke, Marion, Haydock, Julie, Hayes, Orla, Nislev, Lizette Helbo, Hochstodter, Jessica, Hogg, Ashleigh, Hölbing, Manuela, Holland, Maureen, Holsbergen, Maartje, Howard, Linda, Hoyda, Aviya, Hull, Robert, Irish, Jane, Jackson, Wendy, Janssen, Wendy, Jeffrey, Lesley, Jourdan, Sofia, Jutrowska, Izabela, Kaniel, Chava, Karezos, Theofilos, Kelly, Niamh, Kelly, Jessica, Kennedy, Mary, Kennedy, Una, Kibaru, Joyce, Kirkman, Gemma, Klaproth, Janine, Kneese, Corinna, Koch, Andrea, Kokke, Kathleen, Koppelow, Martha, Krause, Sabine, Krauspe, Sabine, Kwakkenbos, Petra, Labarile, Nunzia, Lang, Hannah, Lassailly, Marianne, Leconte, Martine, Lepczynski, Linda, Levell, Emma, Levhar, Nina, Lindhort, Kerstin, Lisle, Jessica, Cauce, Beatriz Lopez, Lorenz, Gabriele, Lovati, Ambra, Lowry, Tracey, Lund, Margareta, Vorderbrügge, Anne Lutz, Maansson, Suzanne, Madapathage, Videsheka, Cheviakoff, Maelys, Magness, Alison, Manley, Orla, Manyoni, Catherine, Marg, Ingke, Marra, Antonella, Martins, Carole, Massella, Arianna, Mathias, Aurore, Mervyn, Danielle, Minsart, Charlotte, Mitchell, Sally, Monks, Kathleen, Montero, Mélanie, Moore, Alson, Moser, Maren, Moss, Alison, Mullen, Angela, Murciano, M. Francisca, Naylor, Deanna, Nehus, Ansgar, Nicholson, Anne, Nöding, Sarah, Nolan, Sinead, Nörenberg, Janet, Northcott, Clare, O'Connell, Jim, O’Kelly, Alison, Orbach-Zingboim, Noam, Orobitg, Judit, Otieno, Charlene, Owen, Charlotte, Patch, Sarah, Pauker, Maor, Pauli, Renate, Pearson, Harriet, Peggy, Falgon, Petit, Séverine, Petrissans, Christine, Piergallini, Simona, Pippard, Lucy, Pitt, Laura, Pócsik, Gabriella, Poher, Yoann, Pomes, Chloé, Pritchard, Lucy, Puchades, Laura, Quaid, Sheena, Rana, Aleem, Raynard, Dana, Reilly, Mykla, Reinert, Sonja, Reinknecht, Manuela, Renner, Baerbel, Reynolds, Rob, Rizzuto, Giulia, Robinson, Matthew, Robrechts, Joke, Rodriguez, Eva M., Rosenblum, Efrat, Russel, Tamlyn, Sadare, Ibiyemi, Salama, Noa, Schakel, Toos, Schauer, Anja, Schiavoni, Elisa, Shaw, Caroline, Shelton, Sarah, Sicart, Virginie, Siouville, Elodie, Smith, Orla, Soude, Théo, Stephenson, Sophie, Stephenson, Elaine, Steppe, Marjan, Sterkx, An, Stickley, Jo, Sugrue, Kathleen, Swietec, Natalia, Tasiaux, Charlotte, Thamu, Bhavneet, Thomas, Susane, Tobi, Ogwa, Touabi, Kahina, Tovi, Shifra, Tregonning, Julie, Turchini, Laura, Unkhoff, Julia, Unruh, Olesya, Uzun, Nurcan, Van Aert, Frauke, Bergh, Sandrine Vanden, Vandenbroucke, Louise, Vansteenkiste, Laura, Vardit, Shay, Vergriete, Valentin, Walker, Elaine, Warner, Eleanor, Watchorn, Olivia, Watson, Ekaterina, Wauthier, Marie-Claire, Weetman, Belgium Maria, Weston, Margaret, West-Petroschka, Wiebke, Wienecke, Susann, Wierling, Kerstin, Wiestler, Miriam, Wilcox, Rebecca, Wilhelmsen, Elva, Williams, Angharad, Williamson, Georgina, Wilson, Deborah, Wistance, Kate, Wortmann, Nicolas, Wurie, Subie, Yadgar, Karin, Young, Gail, Young, Megan, Aucouturier, Julien, Bertin, Marie- Jo, Bougrine, Hasnae, Coisnon, Marie, Defrance, Antoine, Gutierrez, Kati, Harouz, Amel, Jerber, Laure, Khlifi, Aida, Kirati, Amina, Liworo, Nasaladjine, Logoltat, Maude, Mailhat, Charlotte, M'Bayi, Chancely, Medane, Yasmina, Merkhoufa, Dalal, Elhad, Saouda Mohamed, Monthe, Bertille, Moyon, Fanny, Rabiega, Pascaline, Sekela, Jennifer, Thilloy, Charlotte, Hamamouche, Naima, Partisotti, Frederic, Blandin, Patrick, Mokhtari, Hocine, Coutard, Laure, and Doherty, Glen A.

Published
2023
Full Text
View/download PDF

42. P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS

Author

Ilaria Vigliotta, Vincenza Solli, Silvia Armuzzi, Ajsi Kanapari, Andrea Poletti, Barbara Taurisano, Ignazia Pistis, Enrica Borsi, Gaia Mazzocchetti, Marina Martello, Ilaria Rizzello, Lucia Pantani, Giulia Marzocchi, Nicoletta Testoni, Elena Zamagni, Mario Terracciano, Valentina Del Monaco, Marianna Garonzi, Nicolò Manaresi, Michele Cavo, and Carolina Terragna

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

45. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

Author

Macaluso, F, Caprioli, F, Benedan, L, Bezzio, C, Caporali, R, Cauli, A, Chimenti, M, Ciccia, F, D'Angelo, S, Fantini, M, Festa, S, Iannone, F, Lubrano, E, Mariani, P, Papi, C, Provenzano, G, Pugliese, D, Rispo, A, Saibeni, S, Salvarani, C, Variola, A, Zenga, M, Armuzzi, A, Orlando, A, Gerli, R, Macaluso, Fabio Salvatore, Caprioli, Flavio, Benedan, Laura, Bezzio, Cristina, Caporali, Roberto, Cauli, Alberto, Chimenti, Maria Sole, Ciccia, Francesco, D'Angelo, Salvatore, Fantini, Massimo Claudio, Festa, Stefano, Iannone, Florenzo, Lubrano, Ennio, Mariani, Paolo, Papi, Claudio, Provenzano, Giuseppe, Pugliese, Daniela, Rispo, Antonio, Saibeni, Simone, Salvarani, Carlo, Variola, Angela, Zenga, Mariangela, Armuzzi, Alessandro, Orlando, Ambrogio, Gerli, Roberto, Macaluso, F, Caprioli, F, Benedan, L, Bezzio, C, Caporali, R, Cauli, A, Chimenti, M, Ciccia, F, D'Angelo, S, Fantini, M, Festa, S, Iannone, F, Lubrano, E, Mariani, P, Papi, C, Provenzano, G, Pugliese, D, Rispo, A, Saibeni, S, Salvarani, C, Variola, A, Zenga, M, Armuzzi, A, Orlando, A, Gerli, R, Macaluso, Fabio Salvatore, Caprioli, Flavio, Benedan, Laura, Bezzio, Cristina, Caporali, Roberto, Cauli, Alberto, Chimenti, Maria Sole, Ciccia, Francesco, D'Angelo, Salvatore, Fantini, Massimo Claudio, Festa, Stefano, Iannone, Florenzo, Lubrano, Ennio, Mariani, Paolo, Papi, Claudio, Provenzano, Giuseppe, Pugliese, Daniela, Rispo, Antonio, Saibeni, Simone, Salvarani, Carlo, Variola, Angela, Zenga, Mariangela, Armuzzi, Alessandro, Orlando, Ambrogio, and Gerli, Roberto

Abstract

Spondyloarthritis (SpA) is the most frequent extraintestinal manifestation in patients with inflammatory bowel diseases (IBD). When IBD and spondyloarthritis coexist, musculoskeletal and intestinal disease features should be considered when planning a therapeutic strategy. Treatment options for IBD and SpA have expanded enormously over the last few years, but randomized controlled trials with specific endpoints focused on SpA are not available in the IBD setting. To address this important clinical topic, the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and the Italian Society of Rheumatology (SIR) jointly planned to draw updated therapeutic recommendations for IBD-associated SpA using a pseudo-Delphi method. This document presents the official recommendations of IG-IBD and SIR on the management of IBD-associated SpA in the form of 34 statements and 4 therapeutic algorithms. It is intended to be a reference guide for gastroenterologists and rheumatologists dealing with IBD-associated SpA.

Published
2024

46. Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy

Author

Dal Buono A, Gabbiadini R, Solitano V, Vespa E, Parigi TL, Repici A, Spinelli A, and Armuzzi A

Subjects
ulcerative colitis, filgotinib, janus kinase inhibitors, efficacy, safety., Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Arianna Dal Buono,1 Roberto Gabbiadini,1 Virginia Solitano,1,2 Edoardo Vespa,1,2 Tommaso Lorenzo Parigi,1,2 Alessandro Repici,2,3 Antonino Spinelli,1,2,4 Alessandro Armuzzi1,2 1IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 3Endoscopy Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; 4Colon and Rectal Surgery Division, IRCCS Humanitas Research Hospital, Rozzano, Milan, ItalyCorrespondence: Alessandro Armuzzi, IBD Center, Humanitas Research Hospital – IRCCS, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Rozzano, Milan, Italy, Tel +39(0)282245555, Fax +39(0)282242591, Email alessandro.armuzzi@hunimed.euBackground and Aims: Patients affected by moderate-to-severe Ulcerative Colitis (UC) demand a challenging management. Small molecules, administrated as oral agents, have the ambition of overcoming the limitations of the biologic agents (ie, parenteral administration, rapidity of action, primary and secondary non-responsiveness). Beyond tofacitinib, a pan-Janus kinase (JAK) inhibitor already approved for the treatment of moderate-to-severe UC, novel more selective molecules like filgotinib are being currently evaluated in randomized clinical trials. We aimed to review the current evidence on filgotinib, a JAK-1 preferential inhibitor, in the treatment of UC and its place in therapy in the current scenario.Methods: PubMed and EMBASE were searched to identify relevant studies: those investigating the efficacy and safety of filgotinib in the treatment of UC patients were included in this narrative review.Results: The current preliminary data have shown that filgotinib is safe and effective in inducing clinical end endoscopic response in both biologic-naïve and biologic-experienced patients with moderate-to-severe UC, also with high inflammatory burden at baseline. In the SELECTION trial, one case of pulmonary embolism occurred with filgotinib 200 mg induction, and three venous thrombosis cases were observed in the placebo maintenance/LTE; the incidence of herpes zoster was ≤ 1% in all UC treated patients. Filgotinib represents an appealing treatment option for its high selectiveness, route of administration and rapidity of action; cost-effectiveness studies and head-to-head trials are needed to better define its place in therapy.Keywords: ulcerative colitis, filgotinib, Janus kinase inhibitors, efficacy, safety

Published
2022

47. Drug Development in Inflammatory Bowel Diseases: What Is Next?

Author

Petronio, Lorenzo, Dal Buono, Arianna, Gabbiadini, Roberto, Migliorisi, Giulia, Privitera, Giuseppe, Ferraris, Matteo, Loy, Laura, Bezzio, Cristina, and Armuzzi, Alessandro

Abstract

Background/Objectives: Inflammatory bowel diseases (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are chronic conditions requiring long-term therapy to maintain remission and improve quality of life. Despite the approval of numerous drugs, IBD continues to present treatment challenges. This review aims to summarize novel therapeutic target agents in phases II and III of development, including sphingosine-1-phosphate receptor modulators (S1P), anti-interleukin-23 (IL-23), and other small molecules and monoclonal antibodies currently under investigation (e.g., anti-TL1A, obefazimod, NX-13, RIPK-inhibitors). Methods: A comprehensive literature search was conducted up to December 2024 to identify relevant articles published in English over the past three–five years, focusing on phase II/III studies for UC and CD. The search included databases such as PubMed, Google Scholar, and the ClinicalTrials.gov portal. Results: Clinical trials underline the potential of novel immunomodulators, including anti-TL1A, obefazimod, NX-13, RIPK inhibitors, and anti-IL-23p19 agents, as promising therapeutic options for IBD. Anti-IL23p19 therapies, such as risankizumab and mirikizumab, alongside guselkumab, exemplify this class's growing clinical relevance. While some are already in clinical use, others are nearing approval. Conclusions: Ongoing research into long-term safety and the development of personalized treatment strategies remains pivotal to enhance outcomes. Patient stratification and the strategic positioning of these therapies within the expanding treatment landscape are critical for optimizing their clinical impact. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

49. Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach.

Author

Cammarota, Giovanni, Laterza, Lucrezia, Bibbò, Stefano, Fusco, William, Rozera, Tommaso, Di Brino, Eugenio, Porcari, Serena, Scaldaferri, Franco, Ianiro, Gianluca, Gasbarrini, Antonio, and Armuzzi, Alessandro

Subjects
INFLAMMATORY bowel diseases, MEDICAL personnel, VOCATIONAL interests, SOCIAL stigma, PHARMACEUTICAL policy
Abstract

Background: The worldwide prevalence of inflammatory bowel disease (IBD) is increasing, with its potential evolution as a global disease and a consequent increase in its burden on healthcare systems. These estimates do not factor in the 'real' price of IBD, which, beyond curbing career aspirations, instilling social stigma, and impairing the quality of life in patients, could also significantly affect the environment. Aim: To highlight potential areas for intervention and develop management strategies aimed at minimising environmental impacts in the field of IBD over time. Methods: Various aspects of IBD care (organisation of IBD centres, diagnostics and therapeutics) are examined from an environmental sustainability perspective. Results: Each stage, from the patient's means of transport to the hospital to the physician's diagnostic and therapeutic decisions, contribute to CO2 and waste production. Strategies to contain the environmental impact are feasible. Some are easy to implement, such as ensuring the appropriateness of the diagnostic and therapeutic pathway for patients; others need to be implemented in synergy with healthcare providers' policies and pharmaceutical companies. Conclusions: With an inevitable increase in the number of patient visits, endoscopies, laboratory testing, and long‐term therapeutic strategies for IBD, the clinical community should be aware of environmental concerns and investigate possible strategies to reduce the environmental impact of IBD care. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

50. Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It

Author

Giulia Migliorisi, Giovanna Vella, Arianna Dal Buono, Roberto Gabbiadini, Anita Busacca, Laura Loy, Cristina Bezzio, Paolo Vinciguerra, and Alessandro Armuzzi

Subjects
uveitis, episcleritis, scleritis, inflammatory bowel disease, treatment, Cytology, QH573-671
Abstract

Background and aims: Inflammatory bowel diseases (IBD) are multifactorial chronic inflammatory disorders affecting the gastrointestinal tract. However, a broad spectrum of extraintestinal manifestations (EIMs) is associated with IBD, affecting several organs and systems, such as the skin, musculoskeletal and hepatobiliary systems, and, not least, the eye. Approximately 10% of IBD patients can develop ocular EIMs (O-EIMs) with a higher prevalence in Crohn’s disease (CD). Eye-redness, photophobia, pain, and blurred vision are the common symptoms, with a wide rate of severity and clinical impact on the quality of life. This narrative review aims to summarize the prevalence, pathogenesis, and current evidence-based management of O-EIMs, underlying the importance of a holistic approach and specialties collaboration for a prompt diagnosis and treatment. Methods: PubMed was searched up to December 2023 to identify relevant studies investigating the pathogenesis, epidemiology, and treatment of O-EIMs in IBD patients. Results: The mechanisms underlying O-EIMs are partially unknown, encompassing immune dysregulation, shared antigens between the eye and the gut, genetic predisposition, and systemic inflammation driven by high levels of interleukins and cytokines in IBD patients. The complexity of O-EIMs’ pathogenesis reflects in the management of these conditions, varying from topical and systemic steroids to immunomodulatory molecules and biologic therapy, such as anti-tumor necrosis factor (TNF)-alpha. A multidisciplinary approach is the backbone of the management of O-EIMs.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results